In CommitteeFiled Apr 30, 2026
Sponsor: Rep. Rulli, Michael A. [R-OH-6] (R)
Latest Action
Referred to the House Committee on Energy and Commerce.
Apr 30, 2026
Summary
The bill amends the Public Health Service Act to prohibit treating a biologic as a distinct biological product solely on the basis of a clinically inactive protein component. It applies to any biologic covered by the Act’s definition, aiming to prevent unnecessary regulatory barriers and ensure equal access for patients.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Track this bill
Get real-time alerts when HR 8630 changes status, plus AI-powered summaries and stage predictions.
Sign up free